Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/116752

In Collections

This item can be found in the following collections:

Dambrot, C.; Passier, R.; Atsma, D.; Mummery, C.L. (2011)

Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models

Article / Letter to editor
More than 10 years after their first isolation, human embryonic stem cells are finally 'coming of age' in research and biotechnology applications as protocols for their differentiation and undifferentiated expansion in culture become robust and scalable, and validated commercial reagents become available. Production of human cardiomyocytes is now feasible on a daily basis for many laboratories with tissue culture expertise. An additional recent surge of interest resulting from the first production of human iPSCs (induced pluripotent stem cells) from somatic cells of patients now makes these technologies of even greater importance since it is likely that (genetic) cardiac disease phenotypes can be captured in the cardiac derivatives of these cells. Although cell therapy based on replacing cardiomyocytes lost or dysfunctional owing to cardiac disease are probably as far away as ever, biotechnology and pharmaceutical applications in safety pharmacology and drug discovery will probably...Show moreMore than 10 years after their first isolation, human embryonic stem cells are finally 'coming of age' in research and biotechnology applications as protocols for their differentiation and undifferentiated expansion in culture become robust and scalable, and validated commercial reagents become available. Production of human cardiomyocytes is now feasible on a daily basis for many laboratories with tissue culture expertise. An additional recent surge of interest resulting from the first production of human iPSCs (induced pluripotent stem cells) from somatic cells of patients now makes these technologies of even greater importance since it is likely that (genetic) cardiac disease phenotypes can be captured in the cardiac derivatives of these cells. Although cell therapy based on replacing cardiomyocytes lost or dysfunctional owing to cardiac disease are probably as far away as ever, biotechnology and pharmaceutical applications in safety pharmacology and drug discovery will probably impact this clinical area in the very near future. In the present paper, we review the cutting edge of this exciting area of translational research.Show less
cardiac disease model cardiac differentiation cardiomyocyte drug discovery pluripotent stem cell regenerative medicine zinc-finger nucleases human cord blood human fibroblasts rock inhibitor self-renewal functional cardiomyocytes undifferentiated growth maintain pluripotency genetic manipulation embryoid bodies
All authors
Dambrot, C.; Passier, R.; Atsma, D.; Mummery, C.L.
Date
2011-02-15
Journal
Biochemical Journal
Volume
434
Pages
25 - 35
DOI
doi:10.1042/BJ20101707